Ospedale Di Sassuolo S.p.A.

The oncology team is studying endometrial cancer to determine whether adding a new immunotherapy improves survival, while also evaluating maintenance strategies for BRCA wild‑type ovarian cancer after platinum response. A separate trial focuses on women with premature rupture of membranes to see if early active management reduces neonatal respiratory support.

• Immunotherapy plus chemotherapy for advanced endometrial cancer
• Olaparib maintenance in BRCA‑wild type ovarian and peritoneal cancers
• Early induction versus expectant care for PROM in pregnancy

These studies aim to test new therapeutic combinations, improve post‑treatment maintenance, and enhance perinatal outcomes for patients facing gynecologic malignancies and pregnancy complications.

Researchers are comparing a modern tyrosine‑kinase inhibitor with a classic agent in newly diagnosed chronic myeloid leukemia to find the optimal frontline approach. In elderly patients with diffuse large B‑cell lymphoma and high‑grade follicular lymphoma, a pre‑phase regimen with vitamin D supplementation is being tested for better tolerance. Another study examines a reduced‑cycle chemotherapy strategy for high‑burden follicular lymphoma to maintain efficacy while lowering toxicity.

• Frontline nilotinib versus imatinib in chronic phase CML
• Prednisone ± vitamin D prephase before immunochemotherapy for elderly DLBCL
• Shortened chemotherapy combined with immunotherapy for high‑tumor‑burden FL

The goal across these trials is to refine treatment effectiveness, reduce side‑effects, and personalize therapy based on disease biology and patient age.

A trial in metastatic colorectal cancer evaluates first‑line FOLFIRI paired with either bevacizumab or cetuximab, guided by tissue and liquid‑biopsy RAS/BRAF status. Additional investigations focus on biomarker‑driven maintenance with olaparib in ovarian cancer and on novel combinations for advanced solid tumors.

• RAS/BRAF‑guided first‑line therapy selection in mCRC
• Olaparib maintenance after platinum response in ovarian cancer
• Combination strategies to delay recurrence in high‑grade solid tumors

These projects aim to improve progression‑free survival, personalize treatment based on molecular profiles, and explore new maintenance options for patients with advanced malignancies.